Bisoprolol
- Generic Name
- Bisoprolol
- Brand Names
- Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C18H31NO4
- CAS Number
- 66722-44-9
- Unique Ingredient Identifier
- Y41JS2NL6U
- Background
Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure. It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as Carvedilol and Labetalol. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.
- Indication
Bisoprolol is indicated for the treatment of mild to moderate hypertension. It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.
- Associated Conditions
- Atrial Fibrillation, Cardiovascular Events, Chronic Stable Angina Pectoris, Heart Failure, Hypertension, Mild Hypertension, Premature Ventricular Contraction (PVC), Supraventricular Arrhythmias, Moderate Hypertension, Perioperative arrhythmia
Bisoprolol in DMD Early Cardiomyopathy
- Conditions
- Duchenne Muscular DystrophyCardiomyopathy, Dilated
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT03779646
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Early Use of Ivabradine in Heart Failure
- Conditions
- Heart Failure With Reduced Ejection FractionDecompensated Heart Failure
- Interventions
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 50
- Registration Number
- NCT03701880
- Locations
- 🇪🇬
El Demerdash Hospital, Cairo, Egypt
Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 18
- Registration Number
- NCT03485482
- Locations
- 🇪🇬
Faculty of Pharmacy, Cairo, Egypt
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
- Conditions
- Acute Myocardial InfarctionNon-ST Elevation Myocardial InfarctionST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 5000
- Registration Number
- NCT03278509
- Locations
- 🇸🇪
Danderyd Hospital, Cardiac Intensive Care, Danderyd, Stockholms Län, Sweden
A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension
- Conditions
- HypertensionPharmacogenetics
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 233
- Registration Number
- NCT03276598
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 32
- Registration Number
- NCT03226275
- Locations
- 🇨🇳
Xuanwu Hospital, Beijing, China
Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT03026088
- Locations
- 🇨🇳
Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
- Conditions
- Insulin Resistance SyndromeAtherosclerosis, CoronaryAdverse Effect
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Ukrainian Medical Stomatological Academy
- Target Recruit Count
- 43
- Registration Number
- NCT03011775
- Locations
- 🇺🇦
Ukrainian Medical Stomatological Academy, Poltava, Ukraine
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
- Conditions
- Hypertension Resistant to Conventional Therapy
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Sao Jose do Rio Preto Medical School
- Target Recruit Count
- 72
- Registration Number
- NCT02832973
- Locations
- 🇧🇷
Juan Carlos Yugar-Toledo, São José do Rio Preto, São Paulo, Brazil
BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 100
- Registration Number
- NCT02398929
- Locations
- 🇭🇰
Brian Tomlinson, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.